This updated framework underscores the importance of genetic alterations such as IDH mutation status and 1p/19q codeletion in guiding both diagnosis and therapeutic strategies, rendering the older system increasingly obsolete in contemporary glioma management (Cahill et al. 2015; Louis et al. 2007). The gene discussed is IDH2; the disease is central nervous system cancer.